Advertisement

Osteoporosis International

, Volume 29, Issue 2, pp 517–518 | Cite as

Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide

  • T. D. HtetEmail author
  • J. A. Eisman
  • G. J. Elder
  • J. R. Center
Case Report

Abstract

Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.

Keywords

Dystrophic calcification Osteoporosis Teriparatide 

Notes

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E (2011) Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol 65(1):1–12; quiz 3-4.  https://doi.org/10.1016/j.jaad.2010.08.038 CrossRefPubMedGoogle Scholar
  2. 2.
    Boulman N, Slobodin G, Rozenbaum M, Rosner I (2005) Calcinosis in rheumatic diseases. Semin Arthritis Rheum 34(6):805–812.  https://doi.org/10.1016/j.semarthrit.2005.01.016 CrossRefPubMedGoogle Scholar
  3. 3.
    Rosen CJ (2003) The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr 13(1):25–38.  https://doi.org/10.1615/CritRevEukaryotGeneExpr.v13.i1.30 CrossRefPubMedGoogle Scholar
  4. 4.
    Echeverri AF, Ospina FE, Canas CA, Agualimpia A, Suso JP, Tobon GJ et al (2016) Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients. Br J Dermatol 175(5):1049–1051.  https://doi.org/10.1111/bjd.14550 CrossRefPubMedGoogle Scholar
  5. 5.
    Kim SY, Choi HY, Myung KB, Choi YW (2008) The expression of molecular mediators in the idiopathic cutaneous calcification and ossification. J Cutan Pathol 35(9):826–831.  https://doi.org/10.1111/j.1600-0560.2007.00904.x CrossRefPubMedGoogle Scholar
  6. 6.
    Touart DM, Sau P (1998) Cutaneous deposition diseases. Part II. J Am Acad Dermatol 39:527–546CrossRefGoogle Scholar
  7. 7.
    Spanakis EK, Sellmeyer DE (2014) Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment. Osteoporos Int 25(4):1411–1414CrossRefGoogle Scholar
  8. 8.
    Dominguez AR, Goldman SE (2014) Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide. J Am Acad Dermatol 70(2):e41–e42.  https://doi.org/10.1016/j.jaad.2013.10.013 CrossRefPubMedGoogle Scholar
  9. 9.
    Leis-Dosil VM, Rubio-Flores C, Ruiz-Bravo Burguillos E, Díaz-Díaz RM (2013) Calcificaciones vasculares cutáneas secundarias al tratamiento con teriparatida. Actas Dermosifiliogr 104(1):87–88.  https://doi.org/10.1016/j.ad.2012.01.023 CrossRefPubMedGoogle Scholar
  10. 10.
    Patecki M, Lehmann G, Brasen JH, Schmitz J, Bertram A, Berthold LD et al (2017) A case report of severe calciphylaxis - suggested approach for diagnosis and treatment. BMC Nephrol 18(1):137.  https://doi.org/10.1186/s12882-017-0556-z CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Authors and Affiliations

  • T. D. Htet
    • 1
    • 2
    Email author
  • J. A. Eisman
    • 1
    • 2
    • 3
  • G. J. Elder
    • 1
    • 2
    • 4
  • J. R. Center
    • 1
    • 2
    • 3
  1. 1.Department of EndocrinologySt Vincent’s HospitalSydneyAustralia
  2. 2.Osteoporosis and Bone Biology DivisionGarvan Institute of Medical ResearchSydneyAustralia
  3. 3.Faculty of MedicineUniversity of New South WalesSydneyAustralia
  4. 4.Department of Renal MedicineWestmead HospitalSydneyAustralia

Personalised recommendations